Variable | Overall | Non-OAC | OAC | SMD |
---|---|---|---|---|
n | 92,936 | 28,824 | 64,112 | |
Female, n (%) | 40,960 (44.1) | 13,317 (46.2) | 27,643 (43.1) | 0.062 |
Mean Age (SD) | 71.31 (13.46) | 67.66 (16.93) | 72.95 (11.19) | 0.368 |
Concomitant medication (1-year preceding index to 120 days post index), n (%) | ||||
NSAID | 24,623 (26.5) | 8374 (29.1) | 16,249 (25.3) | 0.083 |
Anti-platelet treatment, including low-dose aspirin | 47,108 (50.7) | 14,218 (49.3) | 32,890 (51.3) | 0.039 |
Per-oral antidiabetic drugs | 8482 (9.1) | 1825 (6.3) | 6657 (10.4) | 0.147 |
Acid secretory drugs | 25,861 (27.8) | 7972 (27.7) | 17,889 (27.9) | 0.005 |
Heparin | 5475 (5.9) | 1625 (5.6) | 3850 (6.0) | 0.016 |
Anti-arrhythmic drugs class iii | 6355 (6.8) | 1268 (4.4) | 5087 (7.9) | 0.147 |
Anti-hypertensives | 2049 (2.2) | 422 (1.5) | 1627 (2.5) | 0.077 |
Diuretics | 28,519 (30.7) | 6829 (23.7) | 21,690 (33.8) | 0.225 |
Beta-blockers | 67,830 (73.0) | 16,848 (58.5) | 50,982 (79.5) | 0.468 |
Calcium antagonists | 25,991 (28.0) | 6507 (22.6) | 19,484 (30.4) | 0.178 |
Renin-angiotensin system drugs | 46,452 (50.0) | 10,330 (35.8) | 36,122 (56.3) | 0.420 |
Lipid-modifying drugs | 39,870 (42.9) | 9505 (33.0) | 30,365 (47.4) | 0.297 |
Insulin | 2968 (3.2) | 672 (2.3) | 2296 (3.6) | 0.074 |
Medical history (4 years preceding index), n (%) | ||||
Alcoholism | 1330 (1.4) | 630 (2.2) | 700 (1.1) | 0.086 |
Chronic kidney disease | 4088 (4.4) | 1344 (4.7) | 2744 (4.3) | 0.019 |
Congestive heart failure | 7703 (8.3) | 2625 (9.1) | 5078 (7.9) | 0.043 |
Hypertension | 46,280 (49.8) | 11,825 (41.0) | 34,455 (53.7) | 0.257 |
Liver disease | 911 (1.0) | 350 (1.2) | 561 (0.9) | 0.033 |
Stroke | 6588 (7.1) | 1884 (6.5) | 4704 (7.3) | 0.032 |
Transient ischaemic attack | 3863 (4.2) | 1081 (3.8) | 2782 (4.3) | 0.030 |
Myocardial infarction | 2797 (3.0) | 910 (3.2) | 1887 (2.9) | 0.012 |
Angina Pectoris | 8498 (9.1) | 2617 (9.1) | 5881 (9.2) | 0.003 |
Peripheral artery disease | 3077 (3.3) | 854 (3.0) | 2223 (3.5) | 0.029 |
Pulmonary embolism | 554 (0.6) | 177 (0.6) | 377 (0.6) | 0.003 |
Prior major bleeding (critical organ) | 6370 (6.9) | 2325 (8.1) | 4045 (6.3) | 0.068 |
Type 2 diabetes | 12,501 (13.5) | 2856 (9.9) | 9645 (15.0) | 0.156 |
Dementia | 2207 (2.4) | 1167 (4.0) | 1040 (1.6) | 0.147 |
COPD | 7989 (8.6) | 2362 (8.2) | 5627 (8.8) | 0.021 |
Connective tissue disease | 7234 (7.8) | 2374 (8.2) | 4860 (7.6) | 0.024 |
Leukaemia | 273 (0.3) | 86 (0.3) | 187 (0.3) | 0.001 |
Lymphoma | 720 (0.8) | 264 (0.9) | 456 (0.7) | 0.023 |
Solid tumour | 13,090 (14.1) | 4126 (14.3) | 8964 (14.0) | 0.010 |
Risk scores, mean (SD) | ||||
CHA2dsVASc men | 1.97 (1.44) | 1.58 (1.51) | 2.14 (1.37) | 0.394 |
CHA2dsVASc women | 3.44 (1.41) | 3.13 (1.58) | 3.59 (1.29) | 0.319 |
Modified HAS-BLED Score | 2.04 (1.06) | 1.81 (1.14) | 2.14 (1.01) | 0.301 |
Co-Morbidity Index | 4.45 (2.04) | 4.10 (2.36) | 4.61 (1.85) | 0.241 |